The company's flagship product, the Mitral Butterfly® implant, is a transvascular implant that can be deployed through a catheter onto the beating heart, eliminating the need for open-heart surgery. The implant is designed to offer a reconstruction of the mitral valve in case of mitral valve prolapse and functional regurgitation. The device has a unique physiological design that enables the leaflets to function normally post-implantation, and it takes less than 12 minutes to repair the diseased valve. The Mitral Butterfly® implant has clear advantages over competitors, such as a one-stage delivery and a minimally invasive procedure that reduces hospitalization time and may be available to non-option patients. With over 8 million people in Europe and the US suffering from moderate to severe mitral valve regurgitation, AVVie's product offers a promising solution that can potentially prevent heart failure and provide a safer alternative to open-heart surgery.